- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01451047
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)
February 28, 2012 updated by: Aderans Research Institute
A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Balding Scalp of Subjects With Hair Loss
To evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30326
-
-
Illinois
-
Chicago, Illinois, United States, 60611
-
-
Maryland
-
Chevy Chase, Maryland, United States, 20815
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02116
-
-
New York
-
New York City, New York, United States, 10016
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27609
-
-
Texas
-
Houston, Texas, United States, 77056
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female volunteers 18 to 65 years old, inclusive
- Hair loss consistent with ≥ Grade III-Vertex, IV, VA, V, and VI, based on Norwood-Hamilton Scale providing there is bridging of hair in the anterior edge of the vertex circle.
- Have no clinically significant disease or abnormal laboratory results taken at the screening visit.
Exclusion Criteria:
- Known sensitivity to DMEM/F-12 or any component of the study material.
- Known hypersensitivity to clindamycin hydrochloride, amphotericin B or streptomycin sulfate.
- Subjects who have used minoxidil, or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening.
- A history of drug or alcohol abuse within 1 year of study enrollment.
- Clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator.
- Any clinically significant abnormal laboratory parameters.
- A positive result at screening for human immunodeficiency virus (HIV 1 or 2), Hepatitis B or C, HTLV I/II.
- Dermatologic condition in donation and/or study areas.
- Prior surgery in the treatment area.
- Insufficient hair or scarring in the donor area that might impact cell growth.
- Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: SINGLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in hair number
Time Frame: 51 weeks post-injection
|
51 weeks post-injection
|
Change from baseline in hair width
Time Frame: 51 weeks post-injection
|
51 weeks post-injection
|
Time course of any treatment benefit
Time Frame: 51 weeks post-injection
|
51 weeks post-injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (ACTUAL)
April 1, 2011
Study Registration Dates
First Submitted
October 11, 2011
First Submitted That Met QC Criteria
October 12, 2011
First Posted (ESTIMATE)
October 13, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
February 29, 2012
Last Update Submitted That Met QC Criteria
February 28, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA-0002012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Androgenetic Alopecia
-
University of FloridaWithdrawnFemale Androgenetic AlopeciaUnited States
-
Suzhou Kintor Pharmaceutical Inc,Completed
-
King Edward Medical UniversityCompletedCombination of SVF and PRP for Androgenetic AlopeciaPakistan
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Hope Medicine (Nanjing) Co., LtdRecruitingAndrogenetic AlopeciaChina
-
Indonesia UniversityRecruiting
-
Cassiopea SpAICON Clinical Research; Canfield Scientific Inc.; Ergomed PLC; Pharmapace IncRecruitingAlopecia, AndrogeneticGermany, United States, Poland
-
University of ArizonaTransdermal Cap, Inc.Not yet recruitingAndrogenetic Alopecia
-
Gregory L Smith, MD, MPHRecruitingAndrogenetic AlopeciaUnited States
-
Indonesia UniversityCompletedAndrogenetic AlopeciaIndonesia
Clinical Trials on Autologous cultured dermal and epidermal cells
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States